Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

3
ESMO-MCBS v1.1
Scorecard version: 1

Indication details

Tumour Type
Thoracic Malignancies
Tumour Sub-type
Non-small-cell Lung Cancer
Tumour Sub-Group
EGFR+
Tumour stage
Advanced
Combined Agent(s)
Erlotinib
Control Arm
Erlotinib
Treatment Setting
1st line therapy
Trial Name
JO25567

Primary Outcome(s)

Primary Outcome(s)
PFS (Phase II study)
Evaluated Outcome
PFS
Form(s)
Form 2b

Outcome Data

PFS Control
9.7 months
PFS Gain
6.3 months
PFS HR
0.54 (0.36-0.79)
QoL Comment
No improvement in QoL
Toxicity Comment
Deteriorated toxicity profile not reaching the toxicity thresholds for penalty

Final Score (after adjustments)

Preliminary non-curative score
3
Final non-curative Score
3
Issue date
11.12.2018
Release date
11.12.2018
Last update
13.01.2021

ChT; chemotherapy; DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; FFS, failure-free survival; HR, hazard ratio; iDFS, invasive disease-free survival; ITT, intention to treat; MFS, metastasis-free survival; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PE, point estimate; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate; SD, stable disease; SSA, somatostatin analogue; SSTR, somatostatin receptor; TKI, tyrosine kinase inhibitor, TTP, time to progression

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings